Search results
Results from the WOW.Com Content Network
9 Antiplatelet drug. 10 Anticoagulant. 11 Fibrinolytics. ... Download as PDF; Printable version; In other projects ... List of cardiac pharmaceutical agents.
Low-molecular-weight heparin (LMWH) is a class of anticoagulant medications. [1] They are used in the prevention of blood clots and, in the treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism), and the treatment of myocardial infarction.
Antihypertensive agents comprise multiple classes of compounds that are intended to manage hypertension (high blood pressure). Antihypertensive therapy aims to maintain a blood pressure goal of <140/90 mmHg in all patients, as well as to prevent the progression or recurrence of cardiovascular diseases (CVD) in hypertensive patients with established CVD. [2]
Thrombosis prophylaxis is effective in preventing the formation of blood clots, their lodging in the veins, and their developing into thromboemboli that can travel through the circulatory system to cause blockage and subsequent tissue death in other organs. [1] Clarence Crafoord is credited with the first use of thrombosis prophylaxis in the 1930s.
If prophylaxis is not used after these surgeries, symptomatic VTE has about a 4% chance of developing within 35 days. [158] Following major orthopedic surgery, a blood thinner or aspirin is typically paired with intermittent pneumatic compression , which is the preferred mechanical prophylaxis over graduated compression stockings.
Dalteparin is a low molecular weight heparin.It is marketed as Fragmin.Like other low molecular weight heparins, dalteparin is used for prophylaxis or treatment of deep vein thrombosis and pulmonary embolism to reduce the risk of a stroke or heart attack. [2]
The conditions of DVT only, DVT with PE, and PE only, are all captured by the term venous thromboembolism (VTE). [ 2 ] The initial treatment for VTE is typically either low-molecular-weight heparin (LMWH) or unfractionated heparin , or increasingly with direct acting oral anticoagulants (DOAC).
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.